Rejuvenating Sirtuins: The Rise of a New Family of Cancer Drug Targets

Author(s): Santina Bruzzone, Marco Daniele Parenti, Alessia Grozio, Alberto Ballestrero, Inga Bauer, Alberto Del Rio, Alessio Nencioni.

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 4 , 2013

Abstract:

Sirtuins are a family of NAD+-dependent enzymes that was proposed to control organismal life span about a decade ago. While such role of sirtuins is now debated, mounting evidence involves these enzymes in numerous physiological processes and disease conditions, including metabolism, nutritional behavior, circadian rhythm, but also inflammation and cancer. SIRT1, SIRT2, SIRT3, SIRT6, and SIRT7 have all been linked to carcinogenesis either as tumor suppressor or as cancer promoting proteins. Here, we review the biological rationale for the search of sirtuin inhibitors and activators for treating cancer and the experimental approaches to their identification.

Keywords: Sirtuin modulators, cancer, drug design, epigenetics, drug discovery

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 4
Year: 2013
Page: [614 - 623]
Pages: 10
DOI: 10.2174/1381612811306040614

Article Metrics

PDF: 22